CYP2C19 status and risk of major adverse cardiovascular events in peripheral artery disease: Insights from the EUCLID Trial.
Gutierrez JA, Heizer GM, Jones WS, Rockhold FW, Mahaffey KW, Fowkes FGR, Berger JS, Baumgartner I, Held P, Katona BG, Norgren L, Blomster JI, Hiatt WR, Patel MR.
Gutierrez JA, et al. Among authors: berger js.
Am Heart J. 2020 Nov;229:118-120. doi: 10.1016/j.ahj.2020.07.017. Epub 2020 Aug 16.
Am Heart J. 2020.
PMID: 32950849
Clinical Trial.
No abstract available.